Spinoff Myria Biosciences announces closing of pre-seed funding round
Myria Biosciences AG, a Basel-based pioneer in drug discovery using synthetic biology and AI originating from the D-BSSE, today announces the closing of its pre-seed round. The new funding will enable Myria to expand its scientific team, kickstart its internal drug candidate pipeline, and forge additional partnerships with leading pharmaceutical companies.
Myria's Genetically Engineered Modular Molecular Scaffolds (GEMMS) platform combines SynBio, artificial intelligence and high-throughput screening to engineer complex molecule drugs inspired by natural products to tackle previously undruggable targets. By harnessing data-driven design, Myria is developing a portfolio of highly targeted biopharmaceuticals to address significant unmet medical needs. Myria joins a host of startups hoping to disrupt drug discovery using recent advancements in AI, and differentiates themselves through a SynBio approach that allows them to biologically produce and test novel therapeutic compounds at unprecedented numbers, millions of molecules in a week.
“We are unlocking nature's molecular toolbox through synthetic intelligence. With our GEMMS platform, we can genetically engineer cells to produce novel natural product-inspired compounds beyond the limitations of evolutionary biology. This allows us to systematically generate and optimize molecular therapeutic candidates for highly challenging disease targets.”Dr. Steven Schmitt, D-BSSE alumnus and CEO at Myria Biosciences.
Myria Biosciences is a spin-off integrating cutting edge science from ETH Zurich, the Max Planck Institute, and the Helmholtz Institute for Pharmaceutical Research Saarland. Headquartered in Basel, the Swiss corporation has additional locations in the UK and Germany. Founded in 2021, parts of the technology for this startup originate from the D-BSSE Bioprocess Lab led by Sven Panke.
Investors were led by Creator Fund, a UK venture capital firm with a focus on deep technology startups from Europe’s leading universities.
Find external page media release (issued 20 June 2024) on the external page website of Myria Biosciences.
Learn about other D-BSSE spinoff companies.